Navigation Links
Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
Date:5/16/2011

SAN DIEGO, May 16, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the first quarter ended March 31, 2011.

(Photo:  http://photos.prnewswire.com/prnh/20110516/LA02865)

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

In addition to the announcement of first quarter 2011 financial results, Cardium reported on the Company's near-term goals and milestones including the following: (1) commercialization plans and efforts to support Cardium's Excellagen wound management medical device which is pending clearance of an FDA 510(k) application for marketing and sales in the U.S.; (2) clearance from international health authorities to initiate a planned Phase 3 / Registration clinical trial for Generx® (alferminogene tadenovec/Cardionovo) as a non-surgical, angiogenic treatment option for patients with advanced coronary artery disease who are considering balloon angioplasty and stents or open heart bypass surgery; and (3) expanding the Company's development-stage MedPodium health and wellness brand platform with two new nutraceutical products: Cerex(to support cognitive function) and Alena(a carbohydrate blocker).

First Quarter 2011 Financial HighlightsFor the first quarter ended March 31, 2011, the Company reported a loss from operations of $1.8 million, compared to a loss from operations of $1.5 million for the same period in 2010.  The first quarter 2011 financial results also include an $88,000 favorable adjustment to results of operations for the non-cash change in fair value of certain common stock warrants recorded as "Change in Fair Value of Derivative Liabilities", compared t
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... CHESTERBROOK, Pa. , Aug. 21, 2014 /PRNewswire/ ... AUXL ), a specialty biopharmaceutical company, today announced ... study of collagenase clostridium histolyticum (or CCH) for ... known as cellulite. In the Phase 2a trial, ... (0.48mg) and high (0.84mg)) showed an improvement in ...
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... Drug Administration (FDA or Agency) for the AZ-004 New Drug ... the meeting.  In December 2010, Alexza held the End-of-Review meeting ... October 2010.  A CRL is issued by FDA,s Center for ...
... The United States continues to lead the world in its ... , but emerging markets led by China, India and Brazil ... resources and activity overseas, according to a new PwC report ... . While the United States is expected to maintain its ...
Cached Medicine Technology:Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 2Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 3Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 4Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 5Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA 6Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 2Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 3Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 4Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwC's Medical Technology Innovation Scorecard 5
(Date:8/21/2014)... 21, 2014 The costs paid by consumers ... rise, according to insurer data. The Quotes Pros company is ... time using its tools at http://quotespros.com . , ... homepage connects with providers offering multiple coverage packages for dental ... to the public are now easier to compare using the ...
(Date:8/21/2014)... August 21, 2014 Today, Zane Benefits, ... on the premium tax credits in 2015. , According ... As part of the Affordable Care Act (ACA), premium ... purchase individual health insurance through the Health Insurance Marketplaces. ... eligibility and the amount of the tax credits, updated ...
(Date:8/21/2014)... the coronary arteries of chronic kidney disease patients may ... to a new study in the Journal of ... Researchers at the Johns Hopkins Bloomberg School of Public ... used measures of subclinical atherosclerosis in predicting the risk ... Approximately 50 percent of all patients with chronic kidney ...
(Date:8/21/2014)... University of Texas MD Anderson Cancer Center today announced ... specialized breast screening at a network of community breast ... in late November, MD Anderson will become the exclusive ... Memorial Hermann,s 10 breast care centers, located in Memorial ... Over time, the network will expand to Memorial Hermann,s ...
(Date:8/21/2014)... is eating better and exercising healthy for people with diabetes, ... a new study finds. The study, led by Mark ... Baptist Medical Center in Winston-Salem, N.C., included more than ... Participants ranged in age from 45 to 76, and ... focused on diet and exercise, or to a standard diabetes ...
Breaking Medicine News(10 mins):Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2
... pressure, there were no obvious effects on MKN-45 cells proliferation ... was inhibited and apoptosis improved. It may be that CO2 ... study was performed by a team led by Professor Pei-Wu ... 2008 in the World Journal of Gastroenterology. , There is ...
... ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... an update on recent corporate developments., ... AlphaRx is seeking a listing with the ...
... 21, 2008,Easter Seals Greater Washington-Baltimore Region will honor U.S.,Representative ... for,their efforts on behalf of children and adults with ... at the JW Marriott Hotel,in Washington, D.C, beginning with ... Peterson of WJLA TV will act as Master of ...
... replicate in key organs , , TUESDAY, May 20 (HealthDay News) ... which causes upper respiratory infections and is one of the ... are no drugs specifically approved to treat adenovirus. In part, ... which to test new drugs, something that needs to be ...
... pulmonary disease (COPD) who are in their final years ... pulmonary rehabilitation (PR) as patients who have more years ... lung function, according to new research funded by the ... Thoracic Societys 2008 International Conference in Toronto on Tuesday, ...
... HAE:TSX, MONTREAL, May 20 /PRNewswire-FirstCall/ - ... bio-therapeutics company developing,high-value human plasma-derived protein products ... will present at,Busines$ Meets Finance at the ... at,2:35 p.m., About Busines$ Meets Finance, ...
Cached Medicine News:Health News:AlphaRx Provides Corporate and Development Update 2Health News:Smallpox Drug May Protect Against Common Cold 2Health News:COPD patients benefit more from pulmonary rehab in earlier stages 2Health News:Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre 2
Reference Lab Interface (RLI)© for SRS Software, provides real-time processing of HL7 lab data directly into SRS Freedom Chart ManagerTM, producing an HTML form in the patients chart/tab, whil...
Patient Monitor...
... and a FAM-labeled probe that is designed to ... to detect Flu B. In addition, this ASR ... a separate sample processing control. This ASR requires ... and Texas Red reporter dyes such as the ...
... contains primers and a FAM-labeled probe that ... (RSV). In addition, this ASR contains primers ... sample processing control. This ASR requires an ... Red reporter dyes such as the Cepheid ...
Medicine Products: